Accelr8 Presents Two Studies at ASM 2012 and Receives Acceptance to Present a New Blood Study
DENVER-announced results of two studies that it presented at the 112th annual General Meeting of the American Society for Microbiology (www.asm.org).
The first study used the company’s BACcel™ rapid automated diagnostic system with positive blood cultures to detect a major, complex multi-drug resistance expression type known as “ESBL.” The system’s 3-hour results showed the benefits of the platform decreasing time to result by 1-2 days over the best standard method while maintaining 100% sensitivity and 94% specificity. ESBL resistance has spread globally with hundreds of molecular variants. Early ESBL spread occurred in hospitals, but is now reaching into community-acquired infections. These resistance types are difficult to detect and severely reduce treatment options in the largest family of Gram-negative pathogens.
Go Back
